Stonepine Capital Management LLC Acquires 12,047 Shares of Aprea Therapeutics, Inc. (NASDAQ:APRE)

Stonepine Capital Management LLC raised its holdings in Aprea Therapeutics, Inc. (NASDAQ:APRE) by 8.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 149,221 shares of the company’s stock after acquiring an additional 12,047 shares during the period. Stonepine Capital Management LLC owned about 2.75% of Aprea Therapeutics worth $491,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. BNP Paribas Financial Markets acquired a new stake in shares of Aprea Therapeutics during the fourth quarter valued at about $43,000. LPL Financial LLC acquired a new stake in shares of Aprea Therapeutics during the fourth quarter valued at about $53,000. Finally, Landscape Capital Management L.L.C. acquired a new stake in shares of Aprea Therapeutics during the fourth quarter valued at about $116,000. Institutional investors own 34.19% of the company’s stock.

Aprea Therapeutics Trading Up 3.3%

Shares of APRE stock opened at $1.86 on Friday. The business’s 50-day moving average price is $1.83 and its 200-day moving average price is $2.83. The firm has a market capitalization of $10.28 million, a price-to-earnings ratio of -0.66 and a beta of 1.18. Aprea Therapeutics, Inc. has a 12 month low of $1.41 and a 12 month high of $5.42.

Aprea Therapeutics (NASDAQ:APRE) last posted its quarterly earnings data on Wednesday, May 14th. The company reported ($0.66) EPS for the quarter, missing analysts’ consensus estimates of ($0.65) by ($0.01). The company had revenue of $0.16 million during the quarter. Aprea Therapeutics had a negative return on equity of 57.86% and a negative net margin of 1,029.50%. On average, sell-side analysts predict that Aprea Therapeutics, Inc. will post -2.55 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, Wedbush reissued an “outperform” rating and set a $11.00 price target on shares of Aprea Therapeutics in a research note on Tuesday, March 25th.

Aprea Therapeutics Profile

Aprea Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors.